Hikal Limited reports lower losses as Q2 revenue rises**
Hikal Limited reported consolidated revenue of ₹434 crore in Q2 FY27, up from ₹319 crore a year earlier. EBITDA increased to ₹45 crore from ₹7 crore, while the company reported a net loss of ₹6 crore. Operating performance improved, but the business has not yet returned to profitability. EBITDA margin rose to 10.3% from 2.3% in Q2 FY26. The net loss narrowed from ₹35 crore to ₹6 crore. This is encouraging, though one quarter does not confirm a full recovery. Pharmaceuticals contributed ₹278 crore, or 64% of total revenue, while crop-protection generated ₹156 crore. The pharmaceutical business is now the larger contributor, so its performance will have a major bearing on the next few quarters. Hikal also announced a multi-year CDMO contract with a Europe-based global agrochemical company. It reported that a Swissmedic inspection had been successfully concluded. These developments may improve business visibility, but the financial benefit will depend on execution and commercial order conversion. My view is that higher EBITDA and a narrower loss are positive signs. The next milestone is a return to net profit. I would watch whether margins hold near the current level and whether the new contract starts contributing meaningfully to revenue. View: Early signs of recovery, but confirmation is still needed. Track profitability, cash flow and execution before taking a stronger view. HIKAL



















